Richard Béliveau
Fondateur chez Angiochem, Inc.
Profil
Richard Béliveau is the founder of Katana Biopharma, Inc. (founded in 2016) and Angiochem, Inc. (founded in 2003).
At Angiochem, Inc., he holds the title of Member-Advisory Board.
Dr. Béliveau's former job was at Morneau Sobeco Income Fund, where he held the title of Partner & Head-Investor Relations.
Dr. Béliveau obtained his doctorate degree from Université Laval in 1980.
Postes actifs de Richard Béliveau
| Sociétés | Poste | Début |
|---|---|---|
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Fondateur | 01/01/2003 |
Anciens postes connus de Richard Béliveau
| Sociétés | Poste | Fin |
|---|---|---|
Morneau Sobeco Income Fund
 Morneau Sobeco Income Fund Investment ManagersFinance Morneau Sobeco Income Fund provides human resources consulting and outsourcing services. It provides pension and benefits consulting and outsourcing services to organizations in Canada and the United States. Morneau Sobeco provides consulting services in the areas of absence and disability management, asset management, benefits, communications, compensation, and retirement. The company was founded in 1962 by William F. Morneau Sr. and is headquartered in Toronto, Canada. | Public Communications Contact | 04/01/2011 |
Katana Biopharma, Inc.
 Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Fondateur | - |
Formation de Richard Béliveau
| Université Laval | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Morneau Sobeco Income Fund
Morneau Sobeco Income Fund Investment ManagersFinance Morneau Sobeco Income Fund provides human resources consulting and outsourcing services. It provides pension and benefits consulting and outsourcing services to organizations in Canada and the United States. Morneau Sobeco provides consulting services in the areas of absence and disability management, asset management, benefits, communications, compensation, and retirement. The company was founded in 1962 by William F. Morneau Sr. and is headquartered in Toronto, Canada. | Finance |
Angiochem, Inc.
Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Katana Biopharma, Inc.
Katana Biopharma, Inc. Hospital/Nursing ManagementHealth Services Katana Biopharma, Inc. operates oncology related technology platform. It develops a proprietary technology platform using peptides as a vehicle to specifically deliver existing cytotoxic agents to sortilin receptors, which are overexpressed on cancer cells. The company was founded by Richard Béliveau and Borhane Annabi in 2016 is headquartered in Montréal, Canada. | Health Services |